
Bausch Health Companies BHC
$ 6.75
-3.3%
Quarterly report 2024-Q2
added 08-01-2024
Bausch Health Companies Operating Expenses 2011-2026 | BHC
Annual Operating Expenses Bausch Health Companies
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 4.96 B | 5.53 B | 5.64 B | 5.96 B | 5.71 B | 3.55 B | 3.6 B | 1.82 B | 1.31 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.96 B | 1.31 B | 4.23 B |
Operating Expenses of other stocks in the Drug manufacturers industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
40.3 M | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
38.9 M | - | 0.86 % | $ 117 M | ||
|
Agile Therapeutics
AGRX
|
30.5 M | - | 10.11 % | $ 58.2 M | ||
|
Aerie Pharmaceuticals
AERI
|
213 M | - | - | $ 754 M | ||
|
Alimera Sciences
ALIM
|
71.8 M | - | - | $ 142 M | ||
|
Canopy Growth Corporation
CGC
|
197 M | $ 1.14 | -4.62 % | $ 123 M | ||
|
Cronos Group
CRON
|
154 M | $ 2.56 | 1.24 % | $ 1.35 B | ||
|
Cumberland Pharmaceuticals
CPIX
|
35.2 M | $ 4.74 | 1.94 % | $ 66.6 M | ||
|
Catalent
CTLT
|
512 M | - | - | $ 11.5 B | ||
|
Eagle Pharmaceuticals
EGRX
|
113 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
763 M | - | - | $ 28.9 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
213 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
106 M | - | 2.45 % | $ 38.1 M | ||
|
Evoke Pharma
EVOK
|
12.6 M | - | - | $ 36.6 M | ||
|
DURECT Corporation
DRRX
|
44.6 M | - | - | $ 50.1 M | ||
|
Emergent BioSolutions
EBS
|
558 M | $ 11.08 | 0.82 % | $ 567 M | ||
|
Athenex
ATNX
|
96.7 M | - | -23.39 % | $ 1.76 M | ||
|
Evolus
EOLS
|
107 M | $ 5.05 | -2.88 % | $ 313 M | ||
|
Harrow Health
HROW
|
90.1 M | $ 47.49 | -0.86 % | $ 1.55 B | ||
|
China Pharma Holdings
CPHI
|
2.6 M | $ 1.25 | - | $ 21.8 M | ||
|
Jupiter Wellness
JUPW
|
39.6 M | - | - | $ 33.6 M | ||
|
OrganiGram Holdings
OGI
|
41.4 M | $ 1.62 | 0.62 % | $ 402 M | ||
|
Neoleukin Therapeutics
NLTX
|
55.6 M | - | - | $ 193 M | ||
|
Lannett Company
LCI
|
209 M | - | 1.15 % | $ 7.11 M | ||
|
Sundial Growers
SNDL
|
102 K | $ 1.58 | -2.17 % | $ 3.37 M | ||
|
Organogenesis Holdings
ORGO
|
368 M | $ 3.64 | -3.96 % | $ 479 M | ||
|
Pacira BioSciences
PCRX
|
279 M | $ 19.43 | 1.38 % | $ 899 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
196 M | $ 21.51 | 0.14 % | $ 2.05 B | ||
|
PetIQ
PETQ
|
138 M | - | 1.64 % | $ 400 M | ||
|
Perrigo Company plc
PRGO
|
1.43 B | $ 15.06 | 0.2 % | $ 2.07 B | ||
|
Aurora Cannabis
ACB
|
183 M | $ 4.14 | -2.13 % | $ 86.3 M | ||
|
ProPhase Labs
PRPH
|
47.1 M | - | - | $ 5.07 M | ||
|
Recro Pharma
REPH
|
22.5 M | - | -4.76 % | $ 65.3 M | ||
|
Rockwell Medical
RMTI
|
31.1 M | $ 1.22 | 27.44 % | $ 28.5 M | ||
|
Radius Health
RDUS
|
304 M | - | - | $ 1.42 B | ||
|
Sonoma Pharmaceuticals
SNOA
|
9.18 M | $ 3.33 | 1.06 % | $ 4.13 M | ||
|
Relmada Therapeutics
RLMD
|
104 M | $ 3.93 | 5.01 % | $ 118 M | ||
|
OptiNose
OPTN
|
129 M | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
133 M | $ 12.04 | 4.88 % | $ 855 M | ||
|
Tilray
TLRY
|
1.52 B | $ 8.74 | -7.62 % | $ 5.4 B | ||
|
PLx Pharma
PLXP
|
44.2 M | - | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
130 M | $ 5.59 | 2.19 % | $ 228 M | ||
|
SCYNEXIS
SCYX
|
67.5 M | $ 0.65 | -0.68 % | $ 31.1 M | ||
|
Tricida
TCDA
|
153 M | - | - | $ 3.25 M | ||
|
Veru
VERU
|
44 M | $ 2.53 | -5.95 % | $ 341 M | ||
|
TherapeuticsMD
TXMD
|
9.82 M | $ 2.55 | 14.39 % | $ 26.6 M | ||
|
Viatris
VTRS
|
4.88 B | $ 12.66 | -1.59 % | $ 15.3 B | ||
|
Zomedica Corp.
ZOM
|
14.1 M | - | -0.21 % | $ 98 M | ||
|
cbdMD
YCBD
|
28.9 M | $ 0.83 | -9.94 % | $ 3.58 M |